

CONTENTS

Preface	(vii)
Acknowledgements	(xi)
List of Abbreviations	(xxi)

CHAPTER 1

Global Pharmaceutical Industry: An Overview

1-12

The global pharma markets: The next five years, Outlook for Top Drug Segments, The next ten years: Nine trends to watch

CHAPTER 2

A Short History of Generics

13-36

Generics in the United States, Milestones of Generics: 58 years of advancement, The beginning, Legislation, the primary driver, Kefauver-Harris Amendments of 1962, Hatch-Waxman Act of 1984, Regulatory exclusivities, Generic Drug User Fee Act (GDUFA) 2012, Generics across the world, Current Trends, Future outlook

Cases:

1. Kevadon triggers a significant regulatory reform resulting in landmark legislation! **20**
2. Roche Products Inc Vs Bolar Pharmaceuticals **24**
3. Collaborative non-profit, Civica reduces chronic generic shortages, and predatory pricing! **34**

CHAPTER 3

The Turf Wars

37-172

When the Titans clash, the Turf shrinks, Surviving patent expirations; Defensive strategies by big pharma, Key driver of generics growth, Defensive strategies by Innovator Drug Companies, Strategic patenting, Strategic lobbying, Metabolite defense, Strategic litigation, Pediatric exclusivity, Citizen petition, New, improved successor drug candidates, New improved dosage forms, New uses (Line extensions), Predatory pricing, Aggressive marketing, De-marketing of End-of-the-lifecycle products, Launching own generics, Authorized generics, Reverse payments, Prescription-to-OTC-switches, Strategic alliances, Product lifecycle management strategies, Exploiting Patent expiries: Generic drug firms' offensive strategies, Paragraph IV filings, Strategic lobbying, Strategic litigation, Strategic alliances, Branded generics, Transformational strategies, Invading Innovators turf

Cases:

4. Schering-Plough pushes for extension of Claritin's patent life! **49**
5. Bristol-Myers Squibb's lobbying banks on a legal loophole! **51**
6. Schering-Plough tries the metabolite defense to delay Claritin Generics! **57**
7. Stranger than fiction! BuSpar: How far the companies will go in for delaying a generic entry! **58**
8. Premarin's secret of its enduring success! **65**
9. When you cannot protect, create a barrier to entry legally! **66**
10. Now, you litigate, now you don't! **67**
11. Coumadin's offensive to defend itself! **73**
12. Diprivan deprives generic entry, but not for long! **76**
13. Verelan of AHP and the Applesauce test! **77**
14. WellPoint files a petition for OTC-switch of three non-sedating antihistamine drugs! **79**
15. Citizen petition on Authorized generics! **81**

16. Johnson & Johnson extends its antipsychotic franchise by fielding its blockbuster's metabolite as a new drug! **86**
17. Dilacor XR gets lucky break with its two-way extension of marketing exclusivity, by a new indication and a new formulation! **90**
18. Walmart's Generic Drug Initiative **92**
19. Prozac's patent expiry brings down sales of its branded competitors too! **94**
20. Zocor's predatory pricing strategy! **96**
21. Lilly reduces marketing visits of Cefaclor at the end of the drug's lifecycle! **101**
22. Pfizer launches generic version of its antidepressant, Zoloft! **104**
23. Pfizer launches Neurontin generic through its generics subsidiary, Greenstone! **105**
24. Pitting one generic player against another? **109**
25. Schering Plough's enduring K-Dur! **119**
26. Plavix: Inadequate patent defense costs the company a fortune, and its CEO his job! **121**
27. Cephalon is vigilant on its Provigil! **125**
28. Prilosec, the famous heartburn drug causes heartburn to its competitors! **139**
29. Bayer manages the lifecycle of its Cipro in copybook style! **147**
30. Zocor's multi-pronged defense meets the generic onslaught successfully! **152**
31. Prozac: The world's leading anti-depressant could not survive its post-patent blues! **156**
32. GSK defends its Wellbutrin franchise through strategic partnership! **161**
33. Dr. Reddy's exploits a loophole in the Patent Term Extension Act! **165**
34. Biovail buys Cardizem patent, breathes new life into it! **167**

CHAPTER 4

The Code

173-182

The generics code, A common thread

CHAPTER 5

Strategic Vision

183-198

Impact of vision statements, Five elements of success, Five basic rules

CHAPTER 6

Reaching the Critical Mass

199-274

Critical mass, The prerequisite, What is critical mass?, The acquisition route, Winning moves, Twenty Companies: Key Acquisitions, Mylan, Teva, Sandoz, Pfizer Established Products, Sun Pharma, Aurobindo Pharma, Fosun Pharma, Lupin, Hikma, Dr. Reddy's Laboratories, Cipla, Sawai Pharmaceuticals, STADA, Amneal Pharmaceuticals, Zydus Cadila, Nichi-Iko Pharma, Glenmark, Torrent Pharma, Endo Pharmaceuticals, Biocon

CHAPTER 7

Marketing Mindset

275-300

Product portfolio, Brand building, Top Twenty Companies: Marketing Focus, Mylan, Teva, Sandoz, Pfizer Established Products, Sun Pharma, Aurobindo Pharma, Fosun Pharma, Lupin, Hikma, Dr. Reddy's Laboratories, Cipla, Sawai Pharmaceuticals, STADA, Amneal Pharmaceuticals, Zydus Cadila, Nichi-Iko Pharma, Glenmark, Torrent Pharma, Endo Pharmaceuticals, Biocon

CHAPTER 8

Technology Focus

301-330

Barriers to entry, Gateways, Twenty Companies: Technology Focus, Mylan, Teva, Sandoz, Pfizer Established Products, Sun Pharma,

Aurobindo Pharma, Fosun Pharma, Lupin, Hikma, Dr. Reddy's Laboratories, Cipla, Sawai Pharmaceuticals, STADA, Amneal Pharmaceuticals, Zydus Cadila, Nichi-Iko Pharma, Glenmark, Torrent, Endo Pharmaceuticals, Biocon

Cases:

- 35. Technology wins kudos, business, and an alliance! **306**
- 36. A small step leads to a giant leap in the anti-asthmatic market! **307**
- 37. Value addition through technology! **308**

CHAPTER 9

Focus on Research 331-368

The cost of a new chemical entity, The prerequisites of R&D, New drug development process, Development time, R&D options for international generic drug firms, DOE—A strategy to optimize R&D effort, Contract research opportunities, Top Twenty Companies: R&D focus, Mylan, Teva, Sandoz, Pfizer Established Products, Sun Pharma, Aurobindo Pharma, Fosun Pharma, Lupin, Hikma, Dr. Reddy's Laboratories, Cipla, Sawai Pharmaceuticals, STADA, Amneal Pharmaceuticals, Zydus Cadila, Nichi-Iko Pharma, Glenmark, Torrent Pharma, Endo Pharmaceuticals, Biocon

CHAPTER 10

Intellectual Capital 369-382

Three essential elements, Intellectual capital: Future implications, Four pillars of intellectual capital, How successful companies build intellectual capital, Top Twenty Companies: Intellectual Capital

CHAPTER 11

Integrating Strategically

383-392

Economies of scale, Backward integration, Forward integration, Vertical integration, Top Twenty Companies: Vertical Integration

CHAPTER 12

Internationalizing the Business

393-416

The generic drug industry: The Indian example, Top Twenty Companies: Internationalization, Mylan, Teva, Sandoz, Pfizer Established Products, Sun Pharma, Aurobindo Pharma, Fosun Pharma, Lupin, Hikma, Dr. Reddy's Laboratories, Cipla, Sawai Pharmaceuticals, STADA, Amneal Pharmaceuticals, Zydus Cadila, Nichi-Iko Pharma, Glenmark, Torrent Pharma, Endo Pharmaceuticals, Biocon

CHAPTER 13

Attracting Alliances

417-480

Why are alliances are on the increase? Why ally? Top Twenty Companies: Strategic Alliances, Mylan, Teva, Sandoz, Pfizer Established Products, Sun Pharma, Aurobindo Pharma, Fosun Pharma, Lupin, Hikma, Dr. Reddy's Laboratories, Cipla, Sawai Pharmaceuticals, STADA, Amneal Pharmaceuticals, Zydus Cadila, Nichi-Iko-pharma, Glenmark, Torrent Pharma, Endo Pharmaceuticals, Biocon

CHAPTER 14

Operational Excellence

481-500

How to achieve operational excellence? Cut costs, not corners, A vital tool to achieve operational excellence, Balanced Scorecard, Performance Framework for operations, Positive Reinforcement, Two kinds of commitment, Top Twenty Companies: Operational Excellence

CHAPTER 15

The Secret Sauce

501-534

The secret sauce, Demystifying the 505 (b) pathways, 505 (b) (1), 505 (b) (j), 505 (b) (2), 351 (k) Abbreviated biosimilar pathway, Attractive revenues, an increasing trend

Cases:

38. Teva's Austedo obtains NCE exclusivity via the 505 (b) (2) pathway! **511**
39. Dr. Reddy's AmVaz circumvents a first-to-file generic's 180-day market exclusivity, but succumbs to a patent infringement suit by Pfizer! **512**
40. Hikma's Mitigare avoids the 30-month stay by choosing its reference-listed-drug! **514**
41. Aralez Pharmaceuticals uses the 505 (b) (2) regulatory path to introduce a branded product, Yosprala! **517**
42. Change in solvent makes a super generic deliver superior performance! **518**
43. Superior bioavailability delivers superior performance! **520**
44. Bendeka's new dosing advantages help the brand gain a whopping 70 percent market share in just three months! **522**
45. Zuplenz's differentiating formulation faces competition from generic Ondansetron orally disintegrating tablets! **523**

(xx) | Contents

- 46. The fifth antibacterial drug approved under the GAIN Program could not GAIN sales in the launch year! **525**
- 47. The first follow-on biologic, Omnitrope paves the way for an abbreviated biosimilar pathway! **527**
- 48. Adapt's Narcan intranasal spray 505 (b) (2) application gets a priority and rolling review! **529**

CHAPTER 16

The Contenders

535-576

Evaluation criteria, Strategic vision, Reaching the critical mass, The Marketing mindset, Technology focus, Focus on research, Intellectual capital, Strategic integration, Internationalizing the business, Alliance attractiveness, Operational excellence, Future outlook, Survival of the fittest, The new generics leader on the horizon! A disclaimer

CHAPTER 17

Generics: The Road Ahead

577-584

Pure or conventional generics, Branded generics, Specialty generics, Supergenerics, biosimilars, Emerging trends

CHAPTER 18

Winner's Checklist!

585-594

Winning leadership for an era of change

References

595-632

Index

633-640

About the Author

641